Author(s):
Myat San Yi, Tan Cheng Siang, Soe Lwin, Kay Thi Myint, Khin Than Yee, Nay Lwin, Mardiana binti Kipli, Haris N. Suharjono, Mi Mi Khaing
Email(s):
ymsan@unimas.my
DOI:
10.52711/0974-360X.2021.00481 
Address:
Myat San Yi1, Tan Cheng Siang2, Soe Lwin1, Kay Thi Myint3, Khin Than Yee2, Nay Lwin3, Mardiana binti Kipli1, Haris N. Suharjono4, Mi Mi Khaing1
1Obstetrics and Gynaecology Department, Faculty of Medicine and Health Sciences,
Universiti Malaysia Sarawak.
2Paraclinical Department, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
3Faculty of Medicine, SEGI University.
4Sarawak General Hospital.
*Corresponding Author
Published In:
Volume - 14,
Issue - 5,
Year - 2021
ABSTRACT:
Introduction: Cervical cancer is common cancer and ranked in fourth place in both incidence and mortality worldwide. It is 3rd most common female cancer in Malaysia with a lifetime risk of 1 in 116. Infection with high-risk oncogenic human papillomavirus (HPV) is recognized as one of the substantial risk factors for the development of cervical cancers. Methods: It was a cross-sectional study conducted to determine the prevalence of HPV infection and its subtypes among women with various degrees of abnormal smears, who were seen in the colposcopy clinic of Sarawak General Hospital within six months’ period from January to June 2018. We recruited 56 participants. There were 23 each for an atypical squamous cell of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) and 10 high- grade squamous intraepithelial lesion (HSIL). DNA was extracted, and HPV genotypes were determined via polymerase chain reaction (PCR) using two primer pairs MY09/MY11 and GP5+/GP6+. Results: The age ranged from 23 to 56 years, with a mean age of 42.96 years. HPV was detected in 20 out of 56 (35.7%). There were 6 high-risk oncogenic HPVs (18, 51, 52, 56, 58, 68) detected in participants and the most prevalent subtypes were 18, 52, and 58 (20% each). Four low-risk HPVs detected were 6, 53, 70, and 84. There was a significant association between the severity of cervical lesions and HPV positivity (P < 0.004). HSIL had the highest positive predictive value to have HPV infection as 70% compared to 43.4% of LSIL and 9.3% of ASC-US. Conclusion: Distribution of HPV subtypes from women with abnormal smears from Sarawak indicated a high prevalence of HPV 18, 52, and 58. We also identified HPV 70, which has never been reported in West Malaysia. These findings could contribute valuable information for HPV vaccination strategies, particularly for Sarawakian women.
Cite this article:
Myat San Yi, Tan Cheng Siang, Soe Lwin, Kay Thi Myint, Khin Than Yee, Nay Lwin, Mardiana binti Kipli, Haris N. Suharjono, Mi Mi Khaing. Prevalence of Human Papilloma virus in women with Abnormal Cervical Smears from Sarawak, Malaysia. Research Journal of Pharmacy and Technology. 2021; 14(5):2729-4. doi: 10.52711/0974-360X.2021.00481
Cite(Electronic):
Myat San Yi, Tan Cheng Siang, Soe Lwin, Kay Thi Myint, Khin Than Yee, Nay Lwin, Mardiana binti Kipli, Haris N. Suharjono, Mi Mi Khaing. Prevalence of Human Papilloma virus in women with Abnormal Cervical Smears from Sarawak, Malaysia. Research Journal of Pharmacy and Technology. 2021; 14(5):2729-4. doi: 10.52711/0974-360X.2021.00481 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-65
REFERENCES:
1. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018; 68: 394–424.
2. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110:S4–S7.
3. Azizah AM, Nor Saleha IT, Noor Hashimah A, et al. Malaysian National Cancer Registry Report 2007-2011. National Cancer Registry. Putrajaya. 2016.
4. Bruni L, Albero G, Serrano B, et al. Human papillomavirus and related diseases in Malaysia. Summary Report 2019. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). [Accessed on 4 February 2020]
5. Conway C, Chalkley R, High A, et al. Next-Generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn 2012; 14(2): 104-111. DOI: 10.1016/ j.jmoldx.2011.10.003
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–527.
7. Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107:S2–S5. doi:10.1016/j.ygyno.2007.07.067
8. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32: S16-24. doi:10.1016/j.jcv.2004.12.008.
9. Rodriguez AC, Burk R, Herrero R et al. The natural history of human papillomavirus infection cervical intraepithelial neoplasia among young women guanacaste cohort shortly after initiation sexual life. Sex Transm Dis 2007; 34: 494–502.
10. Aref-Adib M, Freeman-Wang T. Cervical cancer prevention and screening: The role of human papillomavirus testing. Obstet Gynaecol 2016; 18: 251–63. doi: 10.1111/tog.12279.
11. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G: A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445: e224-e231.
12. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991–98.
13. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: Meta-Analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202(12): 1789–1799.
14. Venceslau EM, Bezerra MM, Lopes AC, et al HPV detection using primers MY09/MY11 and GP5+/GP6+ in patients with cytologic and/or colposcopic changes. J Bras Patol Med Lab, 2014; 50(4): 280-285.
15. Sharifah NA, Seeni A, Nurismah MI, et al. Prevalence of Human Papillomavirus in Abnormal Cervical Smears in Malaysian Patients. Asian Pac J Cancer Prev 2009; 10(2): 303–6.
16. Othman N and Othman NH. Detection of human papillomavirus DNA in routine cervical scraping samples: Use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev 2014;15 (5), 2245-2249. DOI: http:// dx.doi.org/ 10.7314/APJCP.2014.15.5.2245
17. Tay S-K and Tay Y-K. The prevalence and significance of high-risk human papilloma virus DNA test in southern Malaysia and Singapore. Aust N Z J Obstet Gynaecol 2009; 49: 323-327.
18. Chong PP, Asyikin N, Rusinahaya M. High Prevalence of Human Papillomavirus DNA Detected in Cervical Swabs from Women in Southern Selangor, Malaysia. Asian Pacific J Cancer Prev 2010; 11: 1645-1651.
19. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38(1): 357-61.
20. Haws ALF, He Q, Rady PL, et al. Nested PCR with the PGMY09/MY11 and GP5+/6+ primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004; 122(1): 87-93.
21. Raub SHA, Isa NM, Zailani HA, et al. Distribution of HPV genotypes in cervical cancers in multi-ethnic Malaysia. Asia Pac J Cancer Prev 2014; 15: 651-656.
22. Tan SC, Ismail MP, Duski DR, et al. Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. Biosci Rep 2018; 38: BSR20171268. doi:10.1042/ BSR20171268.
23. Sainei NE, Kumar VS, Chin YS, et al. High prevalence of human papillomavirus types 56 and 70 identified in the native populations of Sabah, Malaysia. Asia Pac J Cancer Prev 2018; 19: 2807-2813. DOI:10.22034/APJCP.2018.19.10.2807.
24. Chan PKS, Ho WCS, Chan MCW, et al. Meta-Analysis on Prevalence and Attribution of Human Papillomavirus Types 52 and 58 in Cervical Neoplasia Worldwide. PLoS ONE 2014; 9(9): e107573.https://doi.org/10.1371/journal.pone.0107573.
25. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011; 103: 1387–96.
26. Ministry of Health Malaysia. Annual Report [Internet]. 2017 [cited 2020 Feb 7]. Available from: http://www.moh.gov.my/moh/ resources/Penerbitan/Penerbitan%20Utama/Annual%20Report%20MoH%202017.pdf.
27. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012; 131: 2349–2359.
28. Wong LP and Sam IC. Current issues facing introduction in human papillomavirus vaccine in Malaysia. Malays Fam Physician 2007; 2: 47-53.
29. McNamara M, Batur P, Walsh JM, et al. HPV Update: Vaccination, Screening, and Associated Disease. J Gen Intern Med 2016; 31(11): 1360–6. DOI: 10.1007/s11606-016-3725-z.
30. Buang S, Ja’afar S, Pathmanathan I, et al. Human papillomavirus immunisation of adolescent girls: improving coverage through multisectoral collaboration in Malaysia. BMJ 2018; 363: k4602. doi: 10.1136/bmj.k4602.
31. Brotherton JM, Zuber PL, Bloem PJ. Primary prevention of HPV through vaccination: update on the current global status. Curr Obstet Gynecol Rep 2016; 5: 210–224.